
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals Inc. is demonstrating strong financial performance and positive growth indicators, particularly with its product Fanapt, which experienced a 27% year-over-year revenue growth in Q2 2025 and continued to accelerate to a 31% increase in Q3 2025, potentially nearing a $120 million annual run-rate. Additionally, new patient prescriptions for Ponvory reached record highs in Q2 2025, indicating robust demand, with projected gross sales expected to escalate from $9.4 million in 2027 to $172.8 million by 2034, bolstered by strategic commercial initiatives and increased prescriber awareness. The company's investments in promotional programs have resulted in significant increases in prescription metrics for both Fanapt and Ponvory, with notable growth in new prescriptions, reflecting Vanda's successful execution of its commercial strategy amidst an expansive market potential.
Bears say
Vanda Pharmaceuticals Inc reported net product sales of $7.1 million in Q2 2025, a decline of 18% year-over-year, which reflects disruption from recent acquisitions and adjustments in specialty pharmacy channels. The company's revenue outlook is further challenged by the anticipated erosion of exclusivity for its key products by the end of 2027, coupled with the expected rapid decline in Fanapt sales due to competition from new market entrants. Additionally, the commercial trajectory for other treatments, such as Ponvory, remains uncertain following a period of neglect, which has negatively impacted prescriber awareness and could result in significant revenue loss as generics emerge and pricing pressures escalate.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares